| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | cdtB |
| Uniprot No | Q46669 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-269aa |
| 氨基酸序列 | DLTDFRVATWNLQGASATTESKWNINVRQLISGENAVDILAVQEAGSPPS TAVDTGTLIPSPGIPVRELIWNLSTNSRPQQVYIYFSAVDALGGRVNLAL VSNRRADEVFVLSPVRQGGRPLLGIRIGNDAFFTAHAIAMRNNDAPALVE EVYNFFRDSRDPVHQALNWMILGDFNREPADLEMNLTVPVRRASEIISPA AATQTSQRTLDYAVAGNSVAFRPSPLQAGIVYGARRTQISSDHFPVGVSR R |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于cdtB重组蛋白的参考文献概览：
1. **"Cloning and expression of the Campylobacter jejuni cdtB gene in Escherichia coli"**
*作者：Lara-Tejero M, Galán JE*
**摘要**：该研究成功克隆了空肠弯曲杆菌的cdtB基因，并在大肠杆菌中实现了重组蛋白的高效表达。通过体外实验证实重组CdtB具有DNA酶活性，可诱导宿主细胞周期停滞于G2/M期，揭示了其在细胞毒性中的作用机制。
2. **"Characterization of the enzymatic activity of the Helicobacter hepaticus cdtB subunit"**
*作者：Ge Z, Feng Y, Taylor NS等*
**摘要**：作者通过重组表达肝螺杆菌CdtB蛋白，发现其具有磷酸水解酶活性而非传统DNA酶活性。研究揭示了CdtB通过PI3K/Akt信号通路诱导宿主细胞凋亡的新机制，拓展了对不同细菌来源CdtB功能多样性的认识。
3. **"Purification and functional analysis of recombinant Aggregatibacter actinomycetemcomitans CdtB"**
*作者：Shenker BJ, Dlakic M, Walker LP等*
**摘要**：该文献报道了伴放线放线杆菌CdtB重组蛋白的纯化工艺优化，证实其能够与宿主细胞膜胆固醇结合，并通过内吞作用进入细胞。研究发现CdtB的细胞毒性依赖于其保守的催化结构域，为开发特异性抑制剂提供了理论依据。
**Background of CdtB Recombinant Protein**
The Cytolethal Distending Toxin (CDT) is a bacterial toxin produced by several pathogenic bacteria, including *Escherichia coli*, *Helicobacter hepaticus*, and *Campylobacter jejuni*. It comprises three subunits: CdtA, CdtB, and CdtC, with CdtB identified as the critical enzymatic component responsible for its toxic activity. CdtB exhibits structural and functional homology to mammalian DNase I, enabling it to introduce double-strand DNA breaks in host cells. This activity triggers the DNA damage response (DDR), leading to cell cycle arrest at the G2/M phase and subsequent cellular distension, apoptosis, or senescence.
Recombinant CdtB protein is produced via genetic engineering, typically by cloning the *cdtB* gene into expression vectors (e.g., *E. coli* or mammalian systems) followed by purification using affinity chromatography. The recombinant form retains the enzymatic and cytotoxic properties of native CdtB, making it a valuable tool for studying host-pathogen interactions, DNA repair mechanisms, and cell cycle regulation. Its role in inducing genomic instability has also linked it to chronic inflammation and carcinogenesis, highlighting its relevance in cancer research.
Beyond basic research, recombinant CdtB is explored for therapeutic applications. For instance, it serves as a target for neutralizing antibodies or inhibitors to mitigate bacterial infections. Additionally, its immunogenic properties are leveraged in vaccine development against CDT-producing pathogens. However, challenges remain in optimizing its stability, specificity, and delivery for clinical use. Overall, CdtB recombinant protein bridges microbiological, oncological, and biotechnological research, offering insights into both bacterial virulence and eukaryotic cell biology.
×
